EC145 + Doxil = 14.1 months Doxil alone = 16.9 months 2012 Submit to Europe Why would Europe approve after they see this data!! More research needed for phase three research, submission in USA in 2014. That will cost lots of money.
you are inaccurate and misleading. dont understand why your posting innacurate data. \please show the link about your false interpretation.
The results of the interim analysis indicate that the investigational agent EC145 plus Doxil®2 doubled the median progression-free survival compared to Doxil alone, increasing from approximately 3 months to 6 months (hazard ratio of 0.497; p-value3 of 0.014). The preliminary overall survival analysis also indicates a trend toward benefit in the EC145 plus Doxil arm (hazard ratio of 0.425; p-value3 of 0.064). The interim analysis was based on data from 91 women.